title: [Treatment results in children with standard-risk acute lymphoblastic leukemia. Report of the Polish Pediatric Leukemia/Lymphoma Study Group].
abstract: Since 01.07.1993 to 30.09.2002, 640 children (48.2% girls and 51.8% boys) with ALL-SR were diagnosed and treated according to the modified ALL-BFM 90 protocol. In 29 children the treatment was intensified because of poor corticosteroid response. Subject to statistical analysis (Kaplan-Meier method) were thus 611 children with ALL-SR. Among them, 89 patients failed to respond to therapy: 10 (1.6%) early deaths, 15 (2.5%) deaths during I complete remission, 64 (10.5%) relapses. Relapses occurred: 45 (7.4%) in bone marrow, 11 (1.8%) in central nervous system, 4 (0.7%) in testicular and in 4 (0.7%) children combined relapses were observed. Probability rates for 9-year event free survival (EFS) and relapse free survival (RFS) for all patients were 0.77 (0.02) and 0.79 (0.02), respectively. Application of high dose of methotrexate is effective in prevention of relapses, especially meningeal and testicular involvement.
authors.affiliation: Katedra i Klinika Onkologii, Hematologii i Transplantologii Pediatrycznej Akademii Medycznej w Poznaniu. kderwich@poczta.onet.pl
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Derwich
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Kaczmarek-Kanold
authors.forename: Jacek
authors.initials: J
authors.lastname: Wachowiak
authors.forename: Anna
authors.initials: A
authors.lastname: Balcerska
authors.forename: Walentyna
authors.initials: W
authors.lastname: Balwierz
authors.forename: Alicja
authors.initials: A
authors.lastname: Chybicka
authors.forename: Jerzy R
authors.initials: JR
authors.lastname: Kowalczyk
authors.forename: Michał
authors.initials: M
authors.lastname: Matysiak
authors.forename: Danuta
authors.initials: D
authors.lastname: Sońta-Jakimczyk
authors.forename: Mariusz
authors.initials: M
authors.lastname: Wysocki
authors.forename: Lidia
authors.initials: L
authors.lastname: Chełmecka-Hanuszewicz
authors.forename: Teresa
authors.initials: T
authors.lastname: Jackowska
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kołtan
authors.forename: Magdalena
authors.initials: M
authors.lastname: Cwiklińska
authors.forename: Teresa
authors.initials: T
authors.lastname: Odój
authors.forename: Anna
authors.initials: A
authors.lastname: Płoszyńska
authors.forename: Monika
authors.initials: M
authors.lastname: Steczowicz
authors.forename: Violeta
authors.initials: V
authors.lastname: Wojciechowska
authors.forename: Anna
authors.initials: A
authors.lastname: Wójtowicz
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D001853:Bone Marrow / Q000473:pathology; D001859:Bone Neoplasms / Q000556:secondary; D016543:Central Nervous System Neoplasms / Q000556:secondary; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D011044:Poland / Q000453:epidemiology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D012307:Risk Factors; D055502:Secondary Prevention; D016019:Survival Analysis; D013736:Testicular Neoplasms / Q000556:secondary; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D001215:Asparaginase; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin